Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I/Randomised, Double Blind Phase II Study in Metastatic Castration Resistant Prostate Cancer of AZD5363 In Combination With Docetaxel and Prednisolone Chemotherapy (ProCAID)

NCT02121639 is registered in ClinicalTrials.gov with University Hospital Southampton NHS Foundation Trust as lead sponsor.

NCT NCT02121639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02121639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I/Randomised, Double Blind Phase II Study in Metastatic Castration Resistant Prostate Cancer of AZD5363 In Combination With Docetaxel and Prednisolone Chemotherapy (ProCAID)
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Phase
Phase 1/2
Overall status
Completed
Start date
January 29, 2014
Completion date
September 13, 2021
Enrollment
160 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer